Guidelines for treatment of atopic eczema (atopic dermatitis) Part II

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 9, 2012, Pages 1176-1193

  Ring, J ^a,u   Alomar, A ^b   Bieber, T ^c   Deleuran, M ^d   Fink Wagner, A ^e   Gelmetti, C ^f   Gieler, U ^g   Lipozencic, J ^h   Luger, T ⁱ   Oranje, A P ^j   Schafer T ^k   Schwennesen, T ^l   Seidenari, S ^m   Simon, D ⁿ   Stander S ⁱ   Stingl, G ^o   Szalai, S ^p   Szepietowski, J C ^q   Taieb A ^r   Werfel, T ^s   Wollenberg, A ^t   Darsow, U ^a   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF BONN   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e Università di Milano ^*

^f UNIVERSITY OF MILAN   (Italy)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h KBC Zagreb   (Croatia)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^k UNIVERSITY OF LÜBECK   (Germany)

^l Deutscher NEURODERMITIS Bund (DNB)   (Germany)

^m UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁿ Klinik und Poliklinik fur Dermatologie   (Switzerland)

^o UNIVERSITY OF VIENNA   (Austria)

^p HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^q WROCLAW MEDICAL UNIVERSITY   (Poland)

^r HÔPITAL SAINT ANDRÉ   (France)

^s HANNOVER MEDICAL SCHOOL   (Germany)

^t UNIVERSITY OF MUNICH   (Germany)

^u INSTITUTE OF EPIDEMIOLOGY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ALITRETINOIN; ALPHA INTERFERON; AZATHIOPRINE; BIOLOGICAL PRODUCT; BORAGE OIL; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EFALIZUMAB; EMOLLIENT AGENT; ESSENTIAL FATTY ACID; GAMMA INTERFERON; GLUCOCORTICOID; ICOSAPENTAENOIC ACID; INFLIXIMAB; MEPOLIZUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PIMECROLIMUS; PRIMROSE OIL; PSORALEN; RITUXIMAB; STEROID; SUNFLOWER OIL; TACROLIMUS; THYMOPENTIN; UNINDEXED DRUG;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANTIGEN SPECIFICITY; ANTIMICROBIAL THERAPY; ARTICLE; ATOPIC DERMATITIS; BLOOD AUTOTRANSFUSION; BONE MARROW TOXICITY; CANCER RISK; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH EDUCATION; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOPENIA; MASSAGE; MICROBIAL COLONIZATION; MICROEMULSION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; PATIENT COUNSELING; PHOTOTHERAPY; PIGMENT DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PSYCHOSOMATICS; PUVA; RADIATION DOSE; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SKIN BURNING SENSATION; SKIN CANCER; STRESS; SUPERINFECTION; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION;

DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84865085421     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04636.x     Document Type: Article

References (195)

1. Patrizi A, Savoia F, Giacomini F, et al. The effect of summer holidays and sun exposure on atopic dermatitis. G Ital Dermatol Venereol 2009; 144: 463-466.
2. Legat FJ, Wolf P,. Cutaneous sensory nerves: mediators of phototherapeutic effects? Front Biosci 2009; 14: 4921-4931.
3. Gambichler T, Kreuter A, Tomi NS, et al. Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol 2008; 158: 1117-1120.
4. Dotterud LK, Wilsgaard T, Vorland LH, et al. The effect of UVB radiation on skin microbiota in patients with atopic dermatitis and healthy controls. Int J Circumpolar Health 2008; 67: 254-260.
5. Hong SP, Kim MJ, Jung MY, et al. Biopositive effects of low-dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 2008; 128: 2880-2887.
6. Vähävihu K, Ylianttila L, Salmelin R, et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br J Dermatol 2008; 158: 1323-1328.
7. Williams HC, Grindlay DJ,. What's new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol 2008; 33: 685-688.
8. Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160: 652-658.
9. Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77-84.
10. Pugashetti R, Lim HW, Koo J,. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J Dermatolog Treat 2010; 21: 326-330.
11. Chuang TY, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992; 26: 173-177.
12. Tzaneva S, Kittler H, Holzer G, et al,. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010; 162: 655-660.
13. Tominaga M, Tengara S, Kamo A, et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009; 55: 40-46.
14. Mavilia L, Mori M, Rossi R, et al. 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol 2008; 143: 329-337.
15. Wollenschläger I, Hermann J, Ockenfels HM,. [Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopicdermatitis and other inflammatory dermatoses]. Hautarzt 2009; 60: 898-906.
16. Gambichler T,. Management of atopic dermatitis using photo(chemo)therapy. Arch Dermatol Res 2009; 301: 197-203.
17. Syed S, Weibel L, Kennedy H, et al. A pilot study showing pulsed-dye laser treatment improves localized areas of chronic atopic dermatitis. Clin Exp Dermatol 2008; 33: 243-248.
18. Schmitt J, Schäkel K, Fölster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010; 162: 661-668.
19. Hoare C, Li Wan Po A, Williams H,. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1-191.
20. Czech W, Brautigam M, Weidinger G, Schöpf E,. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653-659.
21. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-58.
22. Granlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001; 81: 22-27.
23. Zurbriggen B, Wuthrich B, Cachelin AB, Wili PB, Kagi MK,. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56-60.
24. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebocontrolled, crossover trial. Br J Dermatol 2002; 147: 324-330.
25. Meggitt SJ, Gray JC, Reynolds NJ,. Azathioprine dosed by thiopurine methyltransferase activity for moderateto- severe atopic eczema: a doubleblind, randomised controlled trial. Lancet 2006; 367: 839-846.
26. Murphy LA, Atherton D,. A retropsetive evaluation of azathioprine in severe childhood atopic eczema using thiopurine methlytransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002; 147: 308-315.
27. Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC,. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009; 20: 141-145.
28. Haeck IM, Knol MJ, ten Berge O, van Velsen SGA, de Bruin-Weller MS, Bruijnzeel-Koomen CAFM,. Enteric-coated mycophenolate sodium versus cyclosporine A as long-term treatment in adult patients within severe atopic dermatitis a randomized controlled trial. J Am Acad Dermatol 2011; 64: 1074-1084.
29. Ballester I, Silvestre JF, Pérez-Crespo M, Lucas A,. Severe adult atopic dermatitis: treatment with mycophenolate mofetil in 8 patients. Actas Dermosifiliogr 2009; 100: 883-887.
30. Murray ML, Cohen JB,. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 2007; 32: 23-27.
31. Heller M, Shin HT, Orlow SJ, Schaffer JV,. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157: 127-132.
32. Schram ME, Roekevisch E, Leeflang MMG, Boos JD, Schmitt J, Spuls PI,. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128: 353-359.
33. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ,. An open-label, doseranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007; 156: 346-351.
34. Lyakhovitsky A, Barzilai A, Heyman R, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 2010; 24: 43-49.
35. Hanifin JM, Schneider LC, Leung DY, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28 (2 Pt 1): 189-197.
36. Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000; 42: 1033-1040.
37. Noh G, Lee K,. Successful interferon alpha therapy in atopic dermatitis of Besnier's prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study. Cytokine 2001; 13: 124-128.
38. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158: 808-817.
39. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A,. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 2010; 162: 217-218.
40. Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N,. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008; 122: 423-424.
41. Moul DK, Routhouska SB, Robinson MR, Korman NJ,. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008; 58: 984-989.
42. Takiguchi R, Tofte S, Simpson B, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007; 56: 222-227.
43. Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T,. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010; 24: 837-839.
44. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU,. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121: 122-128.
45. Sedivá A, Kayserová J, Vernerová E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121: 1515-1516.
46. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693-696.
47. Oldhoff JM, Darsow U, Werfel T, et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006; 141: 290-294.
48. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ,. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68-72.
49. Krathen RA, Hsu S,. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-340.
50. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225.
51. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G,. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind study. J Dtsch Dermatol Ges 2010; 8: 990-998.
52. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB,. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008; 29: 530-537.
53. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I,. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55: 168-170.
54. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG,. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 2008; 69: 78-80.
55. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M,. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52: 522-526.
56. Cassano N, Loconsole F, Coviello C, Vena GA,. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 2006; 19: 237-240.
57. Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007; 156: 486-491.
58. Vestergaard C, Deleuran M, Kragballe K,. Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol 2007; 21: 1272-1274.
59. Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 1471-1477.
60. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N,. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118: 1292-1298.
61. Darsow U, Forer I, Ring J,. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep 2011; 11: 277-283.
62. Werfel T, Breuer K, Ruéff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006; 61: 202-205.
63. Ring J,. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107: 597-602.
64. Glover MT, Atherton DJ,. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440-446.
65. Kaufman HS, Roth HL,. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy 1974; 32: 321-330.
66. Warner JO, Price JF, Soothill JF, Hey EN,. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; II: 912-915.
67. Zachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl 1985; 114: 48-54.
68. Galli E, Chini L, Nardi S, et al. Use of specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 1994; 22: 18-22.
69. Mosca M, Albani-Rocchetti G, Vignini MA, Ubezio S, Nume AG, Di Silverio A,. La vaccinoterapia sub-linguale nella dermatite atopica. G Ital Dermatol Venereol 1993; 128: 79-83.
70. Mastrandrea F,. Immunotherapy in atopic dermatitis. Exp Opin Invest Drugs 2001; 10: 1-15.
71. Mastrandrea F, Serio G, Minelli M,. Specific sub-lingual immunotherapy in atopic dermatitis. Results of a 6-year follow up of 35 consecutive patients. Allergol Immunopathol 2000; 28: 54-62.
72. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120: 164-170.
73. Noh G, Lee KJ,. Pilot study of IFN-gamma-induced specific hyposensitization for house dust mites in atopic dermatitis: IFN-gamma-induced immune deviation as a new therapeutic concept for atopic dermatitis. Cytokine 2000; 12: 472-476.
74. Silny W, Czarnecka-Operacz M,. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Dermatitis. Ergebnisse einer placebokontrollierten Doppelblindstudie. Allergologie 2006; 29: 171-183.
75. Darsow U, Behrendt H, Ring J,. Gramineae pollen as trigger factors of atopic eczema: evaluation of diagnostic measures using the atopy patch test. Br J Dermatol 1997; 137: 201-207.
76. Darsow U, Vieluf D, Ring J, for the APT study group. Evaluating the relevance of aeroallergen sensitization in atopic eczema using the tool "atopy patch test": a randomized, double-blind multicenter study. J Am Acad Dermatol 1999; 40: 187-193.
77. Tan B, Weald D, Strickland I, Friedman P,. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15-18.
78. Kühr J, Brauburger J, Zielen S, et al. Efficiacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 274-280.
79. Artik S, Ruzicka T,. Complementary therapy for atopic eczema and other allergic skin diseases. Dermatol Ther 2003; 16: 150-163.
80. Ernst E, Resch K, Mills S,. Complementary medicine-a definition. Br J Gen Pract 1995; 45: 506.
81. Happle R,. The essence of alternative medicine. A dermatologist's view from Germany. Arch Dermatol 1998; 134: 1455-1460.
82. Bielory L,. Complementary medicine for the allergist. Allergy Asthma Proc 2001; 22: 33-37.
83. Fisher P, Ward A,. Complementary medicine in Europe. BMJ 1994; 309: 107-111.
84. Eisenberg D, Davis R, Ettner S, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up nationalsurvey. JAMA 1998; 280: 1569-1575.
85. Triebskorn A, Drosner M,. "Alternativ-medizinische" Behandlungsmethoden in der Beurteilung von Allergikern und chronisch Hautkranken. H+G Zeitschrift für Hautkrankheiten 1989; 64: 487-494.
86. Jensen P,. Use of alternative medicine by patients with atopic dermatitis and psoriasis. Acta Derm Venereol (Stockh) 1990; 70: 421-424.
87. Schäfer T, Riehle A, Wichmann H, Ring J,. Alternative medicine and allergies: Prevalence, patterns of use, and costs. Allergy 2002; 75: 694-700.
88. Baron E, Barzilai D, Johnston G, et al. Epidemiology and health services research. Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, USA and UK. Br J Dermatol 2002; 147: 710-715.
89. Morse P, Horrobin D, Manku M, Stewart J, Allen R, Littlewood S,. Meta-analysis of placebo-controlled studies on the efficacy of epogam in the treatment of atopic eczema. Br J Dermatol 1989; 121: 75-90.
90. Bamford J, Gibson R, Renier C,. Atopic eczema unresponsive to evening primrose oil (linoleic and gamma-linoleic acids). J Am Acad Dermatol 1985; 13: 959-965.
91. Ring J, Kunz B,. Unsaturated fatty acids in the treatment of atopic eczema. In, Ruzicka T, Ring J, Przybilla B, eds. Handbook of Atopic Eczema. Springer, Berlin, 1991: 429-434.
92. Senapati S, Banerjee S, Gangopadhyay D,. Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial. Indian J Dermatol Venereol Leprol 2008; 74: 447-452.
93. Bahmer F, Schaefer J,. Treatment of atopic dermatitis with borage seed oil (glandol)-a time series analytic study. (German). Kinderärztl Prax 1992; 60: 199-202.
94. Borrek S, Hildebrandt A, Forster J,. Gammalinolenic-acid-rich borage seed oil capsules in children with atopic dermatitis. A placebo-controlled double-blind study. Klin Paediatr 1997; 209: 100-104.
95. Buslau M, Thaci D,. Atopic dermatitis: borage oil for systemic therapy. Z Dermatol 1996a; 182: 131-132.
96. Valsecchi R, Di Landro A, Pansera B, Reseghetti A,. Gammalinolenic acid in the treatment of atopic dermatitis (1). J Eur Acad Dermatol Venereol 1996; 7: 77-79.
97. Henz B, Jablonska S, van deKerkhofP, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol 1999; 140: 685-688.
98. Takwale A, Tan E, Agarwal S, et al. Efficacy and tolerability of borage oil in adults and children with atopic eczema: randomised, double blind, placebo controlled, parallel group trial. BMJ 2003; 327: 1385-1388.
99. Koch C, Dölle S, Metzger M, et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008; 158: 786-792.
100. Callaway J, Schwab U, Harvima I, et al. Efficacy of dietary hempseed oil in patients with atopic dermatitis. J Dermatolog Treat 2005; 16: 87-94.
101. Mayser P, Mayer K, Mahloudjian M, et al. A double-blind, randomized, placebo-controlled trial of n-3 versus n-6 fatty acid-based lipid infusion in atopic dermatitis. J Parenter Enteral Nutr 2002; 26: 151-158.
102. Bjorneboe A, Soyland E, Bjorneboe G-E, Rajka G, Drevon C,. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987; 117: 463-469.
103. Gimenez-Arnau A, Barranco C, Alberola M, Wale C, Serrano S, Buchanan M,. Effects of linoleic acid supplements on atopic dermatitis. Adv Exp Med Biol 1997; 433: 285-289.
104. Bjorneboe A, Soyland E, Bjorneboe G, Rajka G, Drevon C,. Effect of ω-3 fatty acid supplement to patients with atopic dermatitis. J Intern Med Suppl 1989; 225: 233-236.
105. Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L,. Dietary supplementation with very long-chain n-3 fatty acids in patients with atopic dermatitis. A double-blind, multicentre study. Br J Dermatol 1994; 130: 757-764.
106. Anstey A, Quigley M, Wilkinson J,. Topical evening primrose oil as treatment for atopic eczema. J Dermatol Treat 1990; 1: 199-201.
107. Ferreira M, Fiadeiro T, Silva M, Soares A,. Topical gamma-linolenic acid therapy in atopic dermatitis. A clinical and biometric evaluation. Allergo J 1998; 7: 213-216.
108. Gehring W, Bopp R, Rippke F, Gloor M,. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. Arzneimittelforschung 1999; 49: 635-642.
109. Bedi M, Shenefelt P,. Herbal therapy in dermatology. Arch Dermatol 2002; 138: 232-242.
110. Patzelt-Wenczler R, Ponce-Pöschl E,. Proof of efficacy of Kamillosan cream in atopic eczema. Eur J Med Res 2000; 5: 171-175.
111. Schempp C, Hezel S, Simon J,. Behandlung der subakuten atopischen dermatitis mit Johanniskraut-Creme-Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbseitendesign. Hautarzt 2003; 54: 248-253.
112. Klövekorn W, Tepe A, Danesch U,. A randomized, double-blind, vehicle-controlled, half-side comparison with a herbal ointment containing Mahonia aquifolium, Viola tricolor and Centella asiatica for the treatment of mild-to-moderate atopic dermatitis. Int J Clin Pharmacol Ther 2007; 45: 583-591.
113. Ernst E,. Adverse effects of herbal drugs in dermatology. Br J Dermatol 2000; 143: 523-529.
114. Giordano-Labadie F, Schwarze H, Bazex J,. Allergic contact dermatitis from camomile used in phytotherapy. Contact Dermatitis 2000; 42: 247.
115. Bircher A, Hauri U, Niederer M, Hohl C, Surber C,. Stealth triamcinolone acetonide in a phytocosmetic cream. Br J Dermatol 2002; 146: 531-532.
116. Koo J, Arain S,. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 1998; 134: 1388-1393.
117. Vender R,. Alternative treatments for atopic dermatitis: a selected review. Skin Therapy Letter 2002; 7: 1-5.
118. Sheehan M, Atherton D,. A controlled trial of traditional chinese medicinal plants in widespread non-exudative atopic eczema. Br J Dermatol 1992; 126: 179-184.
119. Sheehan M, Rustin M, Atherton D, Buckley C, Harris D, Brostoff J,. Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis. Lancet 1992; 340: 13-17.
120. Armstrong N, Ernst E,. The treatment of eczema with chinese herbs: a systematic review of randomised clinical trials. Br J Clin Pharm 1999; 48: 262-264.
121. Sheehan M, Atherton D,. One-year follow up of children treated with Chinese medicinal herbs for atopic eczema. Br J Dermatol 1994; 130: 488-493.
122. Sheehan M, Stevens H, Ostlere L, Atherton D, Brostoff J, Rustin M,. Follow-up of adult patients with atopic eczema treated with Chinese herbal therapy for 1 year. Clin Exp Dermatol 1995; 20: 136-140.
123. Mostefa-Kara N, Pauwels A, Pines E, Biour M, Levy V,. Fatal hepatitis after herbal tea. Lancet 1992; 12: 340.
124. Wang L, Lu L,. Analysis of 162 reported cases of side effects of Chinese medical material. J Beijing Clin Pharm 1992; 5: 50-55.
125. Perharic L, Shaw D, Leon C, De SmetP, Murray V,. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol 1995; 37: 562-566.
126. Latchman Y, Banerjee P, Poulter L, Rustin M, Brostoff J,. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol 1996; 109: 243-249.
127. Fung A, Look P, Chong L, But P, Wong E,. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol 1999; 38: 387-392.
128. Shapira M, Raphaelovich Y, Gilad L, Or R, Dumb A, Ingber A,. Treatment of atopic dermatitis with herbal combination of Eleutherococcus, Achillea millefolium, and Lamium album has no advantage over placebo: a double blind, placebo-controlled, randomized trial. J Am Acad Dermatol 2005; 52: 691-693.
129. Chung-Jen C, Hsin-Su Y,. Acupuncture, electrostimulation, and refelx therapy in dermatology. Dermatol Ther 2003; 16: 87-92.
130. Adaskevich V,. Clinical efficacy and immunoregulatory and neurohumoral effects of MM therapy in patients with atopic dermatitis. Crit Rev Biomed Eng 2000; 28: 11-21.
131. Pfab F, Huss-Marp J, Gatti A, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema-a blinded, randomized, placebo-controlled crossover trial. Allergy 2010; 65: 903-910
132. Pittler M, Armstrong N, Cox A, Collier P, Hart A, Ernst E,. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003; 148: 307-313.
133. Schoeni M, Nikolaizik W, Schoni-Affolter F,. Efficacy trial of bioresonance in children with atopic dermatitis. Int Arch Allergy Immunol 1997; 112: 238-246.
134. Ernst E,. The usage of complementary therapies by dermatological patients: a systematic review. Br J Dermatol 2000; 142: 857-861.
135. Eichler R, Frank H,. Die Homöopathische Behandlung der Neurodermitis bei Kindern und Jugendlichen. Haug, Stuttgart, 2002.
136. Itamura R, Hosoya R,. Homeopathic treatment of Japanese patients with intractable atopic dermatitis. Homoepathy 2003; 92: 108-114.
137. Remy W, Rakoski J, Siebenwirth J, Ulm K, Wiesenauer M,. Classical homoeopathic treatment in atopic dermatitis. Study protocol. Allergologie 1995; 18: 246-252.
138. Siebenwirth J, Lüdtke R, Remy W, Rakoski J, Borelli S, Ring J,. Wirksamkeit von klassisch-homöopathischer Therapie bei atopischem Ekzem. Forsch Komplement Med 2009; 16: 315-323.
139. Schachner L, Field T, Hernandenz-Reif M, Duarte A, Krasnegor J,. Atopic dermatitis symptoms decreased in children following massage therapy. Pediatr Dermatol 1998; 15: 390-395.
140. Anderson C, Lis-Balchin M, Kirk-Smith M,. Evaluation of massage with essential oils on childhood atopic eczema. Phytother Res 2000; 14: 452-456.
141. Halevy S, Sukenik S,. Different modalities of spa therapy for skin diseases at the Dead Sea area. Arch Dermatol 1998; 134: 1416-1420.
142. Harari M, Shani J, Seidl V, Hristakieva E,. Climatotherapy of atopic dermatitis at the Dead Sea: demographic evaluation and cost-effectiveness. Int J Dermatol 2000; 39: 59-69.
143. Shani J, Seidl V, Hristakieva E, Stanimirovic A, Burdo A, Harari M,. Indications, contraindications and possible side-effects of climatotherapy at the Dead-Sea. Int J Dermatol 1997; 36: 481-492.
144. Giryes H, Friger M, Sarov B,. Treatment of atopic dermatitis in the Dead Sea area: biology and therapy of inflammatory skin diseases. International Symposium at the Dead Sea. Dead Sea, Israel, 1997.
145. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Landthaler M, Hofstadter F, Stolz W,. Dead Sea treatment-principle for outpatient use in atopic dermatitis: safety and efficacy of synchronous balneophototherapy using narrowband UVB and bathing in Dead Sea salt solution. Eur J Dermatol 2002; 12: 543-548.
146. Dittmar H, Pflieger D, Schempp C, Schöpf E, Simon J,. Vergleichsstudie Solebäder plus UVA/B versus UVA/B-Monotherapie bei Patienten mit subakuter atopischer Dermatitis. Hautarzt 1999; 50: 649-653.
147. Zimmermann J, Utermann S,. Photo-brine therapy in patients with psoriasis and neurodermatitis. Hautarzt 1994; 45: 849-853.
148. Adachi J, Sumitsuzi H, Endo K, Fukuzumi T, Aoki T,. [Evaluation of the effect of short-term application of deep sea water on atopic dermatitis]. [Japanese] Arerugi 1998; 47: 57-60.
149. Czeizel A, Dobo M,. Postnatal somatic and mental development after periconceptional multivitamin supplementation. Arch Dis Child 1994; 70: 229-233.
150. Fairris G, Perkins P, Lloyd B, Hinks L, Clayton B,. The effect on atopic dermatitis of supplementation with selenium and vitamin E. Acta Derm Venereol 1989; 69: 359-362.
151. Hakagawa R, Ogino Y,. Effects of combination therapy with vitamins E and B2 on skin diseases. Double blind controlled clinical trial. Skin Res 1989; 31: 856-881.
152. Mabin D, Hollis S, Lockwood J, David T,. Pyridoxine in atopic dermatitis. Br J Dermatol 1995; 133: 764-767.
153. Tsoureli-Nikita E, Hercogova J, Lotti T, Menchini G,. Evaluation of dietary intake of vitamin E in the treatment of atopic dermatitis: a study of the clinical course and evaluation of the immunoglobulin E serum levels. Int J Dermatol 2002; 41: 146-150.
154. Sidbury R, Sullivan A, Thadhani R, Camargo CJ,. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol 2008; 159: 245-247.
155. Ewing C, Gibbs A, Ashcroft C, David T,. Failure of oral zinc supplementation in atopic eczema. Eur J Clin Nutr 1991; 45: 507-510.
156. Stücker M, Pieck C, Stoerb C, Niedner R, Hartung J, Altmeyer P,. Topical vitamin B12-a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial. Br J Dermatol 2004; 150: 977-983.
157. Januchowski R,. Evaluation of topical vitamin B(12) for the treatment of childhood eczema. J Altern Complement Med 2009; 15: 387-389.
158. Raap U, Werfel T, Jaeger B, Schmid-Ott G,. Atopische Dermatitis und psychischer Stress. Hautarzt 2003; 54: 925-929.
159. Gieler U,. Psychosomatic and psychobiological aspects of atopic eczema. In, Ring J, Przybilla B, Ruzicka T, eds. Handbook of Atopic Eczema. Springer, Berlin, 2006: 544-556.
160. Koblenzer CS, Koblenzer P,. Chronic intractable atopic eczema. Arch Dermatol 1988; 124: 1673-1677.
161. Kupfer J, Gieler U, Braun A, Niemeier V, Huzler C, Renz H,. Stress and atopic eczema. Int Arch Allergy Immunol 2001; 124: 354-355.
162. Finlay AY,. Measurement of the effect of severe atopic dermatitis on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149-159.
163. Noren P, Melin L,. The effect of combined topical steroid and habit-reversal treatment in patients with atopic dermatitis. Br J Dermatol 1989; 121: 359-366.
164. Ehlers A, Stangier U, Gieler U,. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995; 63: 624-635.
165. Niebel G, ed. Behavioral Medicine of Chronic Dermatological Disorders-Interdisciplinary Perspectives on Atopic Dermatitis and its Treatment. Huber, Bern, 1990.
166. Gieler U, Effendy I,. Psychosomatische Aspekte in der Dermatologie. Akt Dermatol 1984; 10: 103-160.
167. Ring J, Palos E, Zimmermann F,. Psychosomatische Aspekte der Eltern-Kind-Beziehung bei atopischem Ekzem im Kindesalter. Hautarzt 1986; 37: 560-567.
168. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicenter, randomised controlled trial. BMJ 2006; 332: 933-938.
169. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P,. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol 2006; 23: 428-436.
170. Evers AW, Duller P, de Jong EM, et al. Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol 2009; 89: 57-63.
171. Weisshaar E, Diepgen TL, Bruckner T, et al. Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children. Acta Derm Venereol 2008; 88: 234-239.
172. Kupfer J, Gieler U, Diepgen TL, et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J Psychosomatic Res 2010; 68: 353-358.
173. Moore EJ, Williams A, Manias E, Varigos G, Donath S,. Eczema workshops reduce severity of childhood atopic eczema. Australas J Dermatol 2009; 50: 100-106.
174. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. JEADV 2010; 24: 317-328.
175. Shaw M, Morrell DS, Goldsmith LA,. A study of targeted enhanced patient care for pediatric atopic dermatitis (STEP PAD). Pediatr Dermatol 2008; 25: 19-24.
176. Ricci G, Bendandi B, Aiazzi R, Patrizi A, Masi M,. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol 2009; 26: 1-5.
177. Courtenay M, Carey N,. A review of the impact and effectiveness of nurse-led care in dermatology. J Clin Nurs 2007; 16: 122-128.
178. Foster G, Taylor SJ, Elridge SE, Ramsay J, Griffiths CJ,. Self-management education programmes by lay leaders for people with chronic conditions. Cochrane Database Syst Rev 2007; 17: CD005108.
179. Van Os Medendorp H, Ros WJG, Eland-De Kok PCM, et al. Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007; 156: 1235-1244.
180. Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003; 149: 582-589.
181. Laurant M, Reeves D, Hermens R, et al. Substitution of doctors by nurses in primary care. Cochrane Libr 2004. Available at: http://www.mrw.interscience. wiley.com/cochrane/clsysrev/articles/CD001271/frame.html (accessed on 17 October 2010).
182. Smidt S, Thyen U, Chaplin J, Mueller-Godeffroy E, European DISABKIDS Group. Cross-cultural development of a child health care questionnaire on satisfaction, utilization, and needs. Ambul Pediatr 2007; 7: 374-382.
183. Williams HC,. Educational programmes for young people with eczema. One size does not fit all. BMJ 2006; 332: 923-924.
184. Radulescu M, Bock M, Bruckner T, Ellsässer G, Fels H, Diepgen TL,. Health education about occupational allergies and dermatoses for adolescents. J Dtsch Dermatol Ges 2007; 5: 576-581.
185. Gore C, Johnson RJ, Caress AL, Woodcock A, Custovic A,. The information needs and preferred roles in treatment decision-making of parents caring for infants with atopic dermatitis: a qualitative study. Allergy 2005; 60: 938-943.
186. Haubrock M, Daschner A, Diepgen TL, et al. Gesundheitsökonomische Aspekte der Prävention im Rahmen des Modellvorhabens zur besseren Vorsorge und Versorgung von Kindern und Jugendlichen mit atopischem Ekzem (Neurodermitis) Ein nationales, prospektives Multizenterprojekt zur Entwicklung und Erprobung eines standardisierten Patientenschulungsprogramms (GADIS) Gesundh Ökon Qual Manag. 2009; 14: 191-199.
187. Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S,. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev 2007; 18: CD004054.
188. Norreslet M, Jemec GBE, Traulsen JM,. Involuntary autonomy: patients' perceptions of physicians, conventional medicines and risks in the management of atopic dermatitis. Soc Sci Med 2009; 69: 1409-1415.
189. Barbarot S, Gagnayre R, Bernier C, et al. A guide for education programs in atopic dermatitis. Ann Dermatol Venereol 2007; 134: 121-127.
190. Agner T,. Compliance among patients with atopic eczema. Acta Derm Vener Suppl (Stockh) 2005; 215: 33-35.
191. Holm EA, Esmann S, Jemec GB,. Patient education and morbidity in atopic eczema. Dermatol Nurs 2005; 17: 35-46.
192. Gieler U, Kupfer J, Niemeier V, Brosig B, Stangier U,. Atopic eczema prevention programs-a new therapeutic concept for secondary prevention. Dermatol Psychosom 2000; 1: 138-147.
193. Chisolm SS, Taylor SL, Balkrishnan R, Feldman SR,. Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol 2008; 59: 677-683.
194. Stalder JF, Barbarot S,. Atopic dermatitis school: therapeutic education of atopic patients. Rev Prat 2006; 56: 273-276.
195. Asai Y, Kotani K, Kurozawa Y,. The status of Internet access in adult patients with atopic dermatitis in Japan. Tohoku J Exp Med 2006; 210: 37-40.